Skip to content

Zymeworks ZYME Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Charles River Laboratories logo
Charles River LaboratoriesCRL
Summit Therapeutics logo
Summit TherapeuticsSMMT
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's preferred stock, shares authorized?
Zymeworks (ZYME) reported preferred stock, shares authorized of $100M in Q1 2026.
How has Zymeworks's preferred stock, shares authorized changed year-over-year?
Zymeworks's preferred stock, shares authorized decreased by 0.0% year-over-year, from $100M to $100M.
What is the long-term trend for Zymeworks's preferred stock, shares authorized?
Over 3 years (2022 to 2025), Zymeworks's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $100M to $100M.